TY - JOUR
T1 - Translational implications of Th17-skewed inflammation due to genetic deficiency of a cadherin stress sensor
AU - Godsel, Lisa M.
AU - Roth-Carter, Quinn R.
AU - Koetsier, Jennifer L.
AU - Tsoi, Lam C.
AU - Huffine, Amber L.
AU - Broussard, Joshua A.
AU - Fitz, Gillian N.
AU - Lloyd, Sarah M.
AU - Kweon, Junghun
AU - Burks, Hope E.
AU - Hegazy, Marihan
AU - Amagai, Saki
AU - Harms, Paul W.
AU - Xing, Xianying
AU - Kirma, Joseph
AU - Johnson, Jodi L.
AU - Urciuoli, Gloria
AU - Doglio, Lynn T.
AU - Swindell, William R.
AU - Awatramani, Rajeshwar
AU - Sprecher, Eli
AU - Bao, Xiaomin
AU - Cohen-Barak, Eran
AU - Missero, Caterina
AU - Gudjonsson, Johann E.
AU - Green, Kathleen J.
N1 - Funding Information:
This work was supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR041836 to KJG and R01 AR075015 to XB), National Institutes of Health (R37 AR43380 to KJG), and National Cancer Institute (R01 CA228196 to KJG); a Leo Foundation grant (to KJG and ECB); and the Telethon Foundation, Italy (GEP15096 to CM). QRRC and MH were supported by National Institutes of Health T32 Training Grants (T32 CA070085 to QRRC; T32 CA009560 to MH). Additional support was provided by the JL Mayberry endowment (to KJG). JAB was supported by NIH grant K01 AR075087. We acknowledge support and materials from the Northwestern University Skin Biology and Diseases Resource-Based Center (grant P30AR075049). Electron microscopy and some of the imaging was performed at the North-western University Center for Advanced Microscopy, generously supported by NCI Cancer Center Support Grant P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. All histology services were provided by the Northwestern University Mouse Histology and Phenotyping Laboratory, which is supported by NCI P30-CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. JEG, LCT, PWH are supported by NIAMS P30–AR075043. GU is a PhD student within the European School of Molecular Medicine (SEMM). We would like to acknowledge Richard Godsel for development of genotyping methods and antibody validation in regard to the Dsg1–/– mouse.
Funding Information:
This work was supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR041836 to KJG and R01 AR075015 to XB), National Institutes of Health (R37 AR43380 to KJG), and National Cancer Institute (R01 CA228196 to KJG); a Leo Foundation grant (to KJG and ECB); and the Telethon Foundation, Italy (GEP15096 to CM). QRRC and MH were supported by National Institutes of Health T32 Training Grants (T32 CA070085 to QRRC; T32 CA009560 to MH). Additional support was provided by the JL Mayberry endowment (to KJG). JAB was supported by NIH grant K01 AR075087. We acknowledge support and materials from the Northwestern University Skin Biology and Diseases Resource-Based Center (grant P30AR075049). Electron microscopy and some of the imaging was performed at the Northwestern University Center for Advanced Microscopy, generously supported by NCI Cancer Center Support Grant P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. All histology services were provided by the Northwestern University Mouse Histology and Phenotyping Laboratory, which is supported by NCI P30-CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. JEG, LCT, PWH are supported by NIAMS P30?AR075043. GU is a PhD student within the European School of Molecular Medicine (SEMM). We would like to acknowledge Richard Godsel for development of genotyping methods and antibody validation in regard to the Dsg1?/? mouse.
Publisher Copyright:
© 2022, Godsel et al
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Desmoglein 1 (Dsg1) is a cadherin restricted to stratified tissues of terrestrial vertebrates, which serve as essential physical and immune barriers. Dsg1 loss-of-function mutations in humans result in skin lesions and multiple allergies, and isolated patient keratinocytes exhibit increased proallergic cytokine expression. However, the mechanism by which genetic deficiency of Dsg1 causes chronic inflammation is unknown. To determine the systemic response to Dsg1 loss, we deleted the 3 tandem Dsg1 genes in mice. Whole transcriptome analysis of embryonic Dsg1–/– skin showed a delay in expression of adhesion/differentiation/ keratinization genes at E17.5, a subset of which recovered or increased by E18.5. Comparing epidermal transcriptomes from Dsg1-deficient mice and humans revealed a shared IL-17–skewed inflammatory signature. Although the impaired intercellular adhesion observed in Dsg1–/– mice resembles that resulting from anti-Dsg1 pemphigus foliaceus antibodies, pemphigus skin lesions exhibit a weaker IL-17 signature. Consistent with the clinical importance of these findings, treatment of 2 Dsg1-deficient patients with an IL-12/IL-23 antagonist originally developed for psoriasis resulted in improvement of skin lesions. Thus, beyond impairing the physical barrier, loss of Dsg1 function through gene mutation results in a psoriatic-like inflammatory signature before birth, and treatment with a targeted therapy significantly improved skin lesions in patients.
AB - Desmoglein 1 (Dsg1) is a cadherin restricted to stratified tissues of terrestrial vertebrates, which serve as essential physical and immune barriers. Dsg1 loss-of-function mutations in humans result in skin lesions and multiple allergies, and isolated patient keratinocytes exhibit increased proallergic cytokine expression. However, the mechanism by which genetic deficiency of Dsg1 causes chronic inflammation is unknown. To determine the systemic response to Dsg1 loss, we deleted the 3 tandem Dsg1 genes in mice. Whole transcriptome analysis of embryonic Dsg1–/– skin showed a delay in expression of adhesion/differentiation/ keratinization genes at E17.5, a subset of which recovered or increased by E18.5. Comparing epidermal transcriptomes from Dsg1-deficient mice and humans revealed a shared IL-17–skewed inflammatory signature. Although the impaired intercellular adhesion observed in Dsg1–/– mice resembles that resulting from anti-Dsg1 pemphigus foliaceus antibodies, pemphigus skin lesions exhibit a weaker IL-17 signature. Consistent with the clinical importance of these findings, treatment of 2 Dsg1-deficient patients with an IL-12/IL-23 antagonist originally developed for psoriasis resulted in improvement of skin lesions. Thus, beyond impairing the physical barrier, loss of Dsg1 function through gene mutation results in a psoriatic-like inflammatory signature before birth, and treatment with a targeted therapy significantly improved skin lesions in patients.
UR - http://www.scopus.com/inward/record.url?scp=85123969361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123969361&partnerID=8YFLogxK
U2 - 10.1172/JCI144363
DO - 10.1172/JCI144363
M3 - Article
C2 - 34905516
AN - SCOPUS:85123969361
SN - 0021-9738
VL - 132
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 3
M1 - 144363
ER -